CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

Immunosuppressive tumor microenvironments can restrain antitumor immunity, particularly in pancreatic ductal adenocarcinoma (PDA). Because CD40 activation can reverse immune suppression and drive antitumor T cell responses, we tested the combination of an agonist CD40 antibody with gemcitabine chemo...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Beatty, Gregory L., Chiorean, Elena G., Fishman, Matthew P., Saboury, Babak, Teitelbaum, Ursina R., Sun, Weijing, Huhn, Richard D., Song, Wenru, Li, Dongguang, Sharp, Leslie L., Torigian, Drew A., O’Dwyer, Peter J., Vonderheide, Robert H.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2011
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3406187/
https://ncbi.nlm.nih.gov/pubmed/21436454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/science.1198443
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller